% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Raut:144260,
      author       = {J. R. Raut$^*$ and Z. Guan$^*$ and P. Schrotz-King$^*$ and
                      H. Brenner$^*$},
      title        = {{W}hole-blood {DNA} {M}ethylation {M}arkers for {R}isk
                      {S}tratification in {C}olorectal {C}ancer {S}creening: {A}
                      {S}ystematic {R}eview.},
      journal      = {Cancers},
      volume       = {11},
      number       = {7},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2019-01780},
      pages        = {912},
      year         = {2019},
      abstract     = {DNA methylation profiles within whole-blood samples have
                      been reported to be associated with colorectal cancer (CRC)
                      occurrence and might enable risk stratification for CRC. We
                      systematically reviewed and summarized studies addressing
                      the association of whole-blood DNA methylation markers and
                      risk of developing CRC or its precursors. We searched PubMed
                      and ISI Web of Knowledge to identify relevant studies
                      published until 12th November 2018. Two reviewers
                      independently extracted data on study population
                      characteristics, candidate genes, methylation measurement
                      methods, methylation levels of patients in comparison to
                      healthy controls, p-values, and odds ratios of the markers.
                      Overall, 19 studies reporting 102 methylation markers for
                      risk assessment of colorectal neoplasms met our inclusion
                      criteria. The studies mostly used Methylation Specific
                      Polymerase Chain Reaction (MS-PCR) for assessing the
                      methylation status of a defined set of genes. Only two
                      studies applied array-based genome-wide assays to assess the
                      methylation levels. Five studies incorporated panels
                      consisting of 2-10 individual methylation markers to assess
                      their potential for stratifying the risk of developing
                      colorectal neoplasms. However, none of these associations
                      was confirmed in an independent cohort. In conclusion,
                      whole-blood DNA methylation markers may be useful as
                      biomarkers for risk stratification in CRC screening, but
                      reproducible risk prediction algorithms are yet to be
                      established by large scale epigenome-wide studies with
                      thorough validation of results in prospective study cohorts
                      including large screening populations. The possibilities of
                      enhancing predictive power by combining methylation data
                      with polygenetic risk scores and environmental risk factors
                      need to be explored.},
      subtyp        = {Review Article},
      cin          = {C070 / C120 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31261771},
      doi          = {10.3390/cancers11070912},
      url          = {https://inrepo02.dkfz.de/record/144260},
}